Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 13-14/2014

01.07.2014 | main topic

Vitiligo: what’s new in the psycho-neuro-endocrine-immune connection and related treatments

verfasst von: MD Torello Lotti, Matteo Zanardelli, MD Angelo Massimiliano D’Erme

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Vitiligo is an acquired depigmentary skin disorder of unknown origin characterized by well-demarcated, white macules of varying size and distribution. Despite relevant new research and progresses, why melanocytes disappear to induce the characteristic achromic lesions of vitiligo is not fully understood. In spite of recent findings implicating genetic, immune and oxidative stress factors, the exact pathogenesis of vitiligo remains obscure. An innovative concept based on a functional cross-talk between the nervous and immune system is emerging. Neuropeptides released from peripheral nerve endings could synergize with new cytokines to adversely affect melanocyte function and viability. Evidence is increasing regarding the role of neuropeptides in the pathogenesis of vitiligo and a new winning approach to vitiligo therapy based on neuropeptides regulation is at the horizon.
Literatur
1.
Zurück zum Zitat Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, Dalai S, Begum R. Vitiligo: interplay between oxidative stress and immune system. Experimental Dermatology. 2013;22:245–50. PubMedCrossRef Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, Dalai S, Begum R. Vitiligo: interplay between oxidative stress and immune system. Experimental Dermatology. 2013;22:245–50. PubMedCrossRef
2.
Zurück zum Zitat Lotti T, Hercogova J, editors. Vitiligo: problems and solutions. New York: Marcel Dekker; 2004. S. 323–34. Lotti T, Hercogova J, editors. Vitiligo: problems and solutions. New York: Marcel Dekker; 2004. S. 323–34.
3.
Zurück zum Zitat Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M. The writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19. PubMedCrossRef Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M. The writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19. PubMedCrossRef
4.
5.
Zurück zum Zitat Hercogová J, Schwartz RA, Lotti TM. Classification of vitiligo: a challenging endeavor. Dermatol Ther. 2012;25(Suppl 1):10–6. CrossRef Hercogová J, Schwartz RA, Lotti TM. Classification of vitiligo: a challenging endeavor. Dermatol Ther. 2012;25(Suppl 1):10–6. CrossRef
6.
Zurück zum Zitat Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1–13. PubMedCentralPubMedCrossRef Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1–13. PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100. PubMedCrossRef Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100. PubMedCrossRef
8.
Zurück zum Zitat Linthorst Homan MW, Sprangers MA, de Korte J, Bos JD, van der Veen JP. Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol. 2008;144(8):1062–4. PubMedCrossRef Linthorst Homan MW, Sprangers MA, de Korte J, Bos JD, van der Veen JP. Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol. 2008;144(8):1062–4. PubMedCrossRef
9.
Zurück zum Zitat Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35(5 Pt 1):671–4. PubMedCrossRef Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35(5 Pt 1):671–4. PubMedCrossRef
10.
Zurück zum Zitat Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun. 2008;10:227–43. PubMedCrossRef Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun. 2008;10:227–43. PubMedCrossRef
11.
Zurück zum Zitat Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91. PubMedCrossRef Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91. PubMedCrossRef
12.
Zurück zum Zitat Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity. 2001;34:65–77. PubMedCrossRef Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity. 2001;34:65–77. PubMedCrossRef
13.
Zurück zum Zitat Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, De Benedette MA. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol. 2003 Sep;121(3):550–6. PubMedCrossRef Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, De Benedette MA. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol. 2003 Sep;121(3):550–6. PubMedCrossRef
14.
Zurück zum Zitat Steitz J, Wenzel J, Gaffal E, Tuting T. Initiation and regulation of CD8 + T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol. 2004;83(11–12):797–803. PubMedCrossRef Steitz J, Wenzel J, Gaffal E, Tuting T. Initiation and regulation of CD8 + T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol. 2004;83(11–12):797–803. PubMedCrossRef
15.
Zurück zum Zitat Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97(6):1078–80. PubMedCrossRef Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97(6):1078–80. PubMedCrossRef
16.
Zurück zum Zitat Farrokhi S, Hojjat-Farsangi M, Noohpisheh MK, Tahmasbi R, Rezaei N. Assessment of the immune system in 55 Iranian patients with vitiligo. J Eur Acad Dermatol Venereol. 2005;19(6):706–11. PubMedCrossRef Farrokhi S, Hojjat-Farsangi M, Noohpisheh MK, Tahmasbi R, Rezaei N. Assessment of the immune system in 55 Iranian patients with vitiligo. J Eur Acad Dermatol Venereol. 2005;19(6):706–11. PubMedCrossRef
17.
Zurück zum Zitat Lotti T, D’Erme AM, Hercogova J. The role of neuropeptides in the control of regional immunity. Clin Dermatol. (In press). Lotti T, D’Erme AM, Hercogova J. The role of neuropeptides in the control of regional immunity. Clin Dermatol. (In press).
18.
Zurück zum Zitat Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–79. PubMedCrossRef Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–79. PubMedCrossRef
19.
Zurück zum Zitat Al’Abadie MSK, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol. 1994;131:160–5. Al’Abadie MSK, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol. 1994;131:160–5.
20.
Zurück zum Zitat Nellhiius G, Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology. 1970;20:965–74. CrossRef Nellhiius G, Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology. 1970;20:965–74. CrossRef
21.
Zurück zum Zitat Silvan M. The psychological aspects of vitiligo. Cutis. 2004;73(3):163–7. PubMed Silvan M. The psychological aspects of vitiligo. Cutis. 2004;73(3):163–7. PubMed
22.
Zurück zum Zitat Lotti T, Bianchi B, Ghersetich I, Brazzini B, Hercogova J. Can the brain inhibit inflammation generated in the skin? The lesson of gamma-melanocyte-stimulating hormone. Int J Dermatol. 2002;41(6):311–8. PubMedCrossRef Lotti T, Bianchi B, Ghersetich I, Brazzini B, Hercogova J. Can the brain inhibit inflammation generated in the skin? The lesson of gamma-melanocyte-stimulating hormone. Int J Dermatol. 2002;41(6):311–8. PubMedCrossRef
23.
Zurück zum Zitat Lotti T, Hautmann G, Panconesi E. Neuropeptides in skin. J Am Acad Dermatol. 1995;33(3):482–96. PubMedCrossRef Lotti T, Hautmann G, Panconesi E. Neuropeptides in skin. J Am Acad Dermatol. 1995;33(3):482–96. PubMedCrossRef
24.
Zurück zum Zitat Lotti T, Bianchi B, Panconesi E. Neuropeptides and skin disorders. The new frontiers of neuro-endocrine-cutaneous immunology. Int J Dermatol. 1999;38(9):673–5. PubMedCrossRef Lotti T, Bianchi B, Panconesi E. Neuropeptides and skin disorders. The new frontiers of neuro-endocrine-cutaneous immunology. Int J Dermatol. 1999;38(9):673–5. PubMedCrossRef
25.
Zurück zum Zitat Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatol Clin. 2005;23(4):601–8. PubMedCrossRef Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatol Clin. 2005;23(4):601–8. PubMedCrossRef
26.
Zurück zum Zitat Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol Clin. 2005;23(4):609–17. PubMedCrossRef Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol Clin. 2005;23(4):609–17. PubMedCrossRef
27.
Zurück zum Zitat Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP, Luiten RM. Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol. 2013;168(5):1003–11. PubMedCrossRef Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP, Luiten RM. Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol. 2013;168(5):1003–11. PubMedCrossRef
28.
Zurück zum Zitat Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol Venereol. 2012;26(7):861–7. PubMedCrossRef Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol Venereol. 2012;26(7):861–7. PubMedCrossRef
29.
Zurück zum Zitat D’Erme AM, Zanieri F, Campolmi E, Santosuosso U, Betti S, Agnoletti AF, Cossidente A, Lotti T. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol. 2012 Sep 11. D’Erme AM, Zanieri F, Campolmi E, Santosuosso U, Betti S, Agnoletti AF, Cossidente A, Lotti T. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol. 2012 Sep 11.
30.
31.
Zurück zum Zitat Falabella R, Barona MI, Echeverri IC, Alzate A. Substance P may play a part during depigmentation in vitiligo. A pilot study. J Eur Acad Dermatol Venereol. 2003 May;17(3):355–6. PubMedCrossRef Falabella R, Barona MI, Echeverri IC, Alzate A. Substance P may play a part during depigmentation in vitiligo. A pilot study. J Eur Acad Dermatol Venereol. 2003 May;17(3):355–6. PubMedCrossRef
32.
Zurück zum Zitat Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265–266:143–9. PubMedCentralPubMedCrossRef Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265–266:143–9. PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8. PubMedCrossRef Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8. PubMedCrossRef
34.
Zurück zum Zitat Slominski A, Wortsman J, Pisarchik A, Zbytec B, Linton EA, Mazurkiewicz JE, Wei ET. Cutaneous expression of corticotrophin releasing hormone (CRH), urocortin and CRH receptors. FASEB J. 2001;15(10):1678–93. PubMedCrossRef Slominski A, Wortsman J, Pisarchik A, Zbytec B, Linton EA, Mazurkiewicz JE, Wei ET. Cutaneous expression of corticotrophin releasing hormone (CRH), urocortin and CRH receptors. FASEB J. 2001;15(10):1678–93. PubMedCrossRef
35.
Zurück zum Zitat Slominski AT, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155–228. PubMedCrossRef Slominski AT, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155–228. PubMedCrossRef
36.
Zurück zum Zitat Kingo K, Aunin E, Karelson M, Philips MA, Rätsep R, Silm H, Vasar E, Soomets U, Kõks S. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007;48(2):113–22. PubMedCrossRef Kingo K, Aunin E, Karelson M, Philips MA, Rätsep R, Silm H, Vasar E, Soomets U, Kõks S. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007;48(2):113–22. PubMedCrossRef
37.
Zurück zum Zitat Reimann E, Kingo K, Karelson M, Salum T, Aunin E, Reemann P, Abram K, Vasar E, Silm H, Kõks S. Analysis of the expression profile of CRH-POMC system genes in vitiligo skin biopsies. J Dermatol Sci. 2010;60(2):125–8. PubMedCrossRef Reimann E, Kingo K, Karelson M, Salum T, Aunin E, Reemann P, Abram K, Vasar E, Silm H, Kõks S. Analysis of the expression profile of CRH-POMC system genes in vitiligo skin biopsies. J Dermatol Sci. 2010;60(2):125–8. PubMedCrossRef
38.
Zurück zum Zitat Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111(1):80–8. PubMedCrossRef Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111(1):80–8. PubMedCrossRef
39.
Zurück zum Zitat Hristakieva E, Lazarova R, Lazarov N, et al. Markers for vitiligo related neuropeptides in human skin nerve fibres. Acta Med Croatica. 2000;54:53–7. PubMed Hristakieva E, Lazarova R, Lazarov N, et al. Markers for vitiligo related neuropeptides in human skin nerve fibres. Acta Med Croatica. 2000;54:53–7. PubMed
40.
Zurück zum Zitat Miniati A, Weng Z, Zhang B, Therianou A, Vasiadi M, Nicolaidou E, Stratigos AJ, Antoniu C, Theoharides TC. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol. 2014;39(1):54–7. PubMedCrossRef Miniati A, Weng Z, Zhang B, Therianou A, Vasiadi M, Nicolaidou E, Stratigos AJ, Antoniu C, Theoharides TC. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol. 2014;39(1):54–7. PubMedCrossRef
41.
Zurück zum Zitat Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol. 1990;95:100–4. CrossRef Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol. 1990;95:100–4. CrossRef
42.
Zurück zum Zitat Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139–40. PubMedCrossRef Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139–40. PubMedCrossRef
Metadaten
Titel
Vitiligo: what’s new in the psycho-neuro-endocrine-immune connection and related treatments
verfasst von
MD Torello Lotti
Matteo Zanardelli
MD Angelo Massimiliano D’Erme
Publikationsdatum
01.07.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0288-7